MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award
CANTON, Mich. (May 28, 2025) – MMS, a global, data-focused clinical research organization (CRO), has been named a finalist in the 2025 Fierce CRO Awards in the category of Excellence in Client Service and Partnership. Judged on the ability of MMS to demonstrate innovation and impact, measurable outcomes, and scalability, MMS stood out as one of the top three organizations with a strong commitment to building collaborative, long-term sponsor relationships.
Additionally, MMS founder and CEO Dr. Uma Sharma has been shortlisted as a finalist for the CRO Champion Award, a category that celebrates leaders whose vision and values have shaped the future of clinical development.
“This recognition is meaningful because it reflects how we show up for our clients every day. At MMS, we have a vision that scientific integrity and client trust are interwoven and are the basis of our successful partnerships. That belief has shaped everything that we have built globally at MMS,” said Dr. Sharma. “Our Sponsors, large, mid-size and biotech, choose us to walk with them through their complex challenges in bringing new medicines to patients. That responsibility humbly guides our entire team. It is a privilege to collaborate across so many drug development areas and be recognized.”
Under Dr. Sharma’s leadership, the organization has grown from a one-person consultancy into a 1,000-person global CRO known for its creative strategies, nimble execution, and scientific integrity, all with a Sponsor-first mindset. MMS has maintained a client and colleague retention rate that far exceeds industry benchmarks, with many sponsor relationships spanning well over a decade and with many colleagues part of MMS since inception. The Excellence in Client Service and Partnership nomination recognized how MMS partners with clients navigating complex R&D challenges. These include regulatory strategy and submissions, accelerated development pathways, trial design, and delivering end-to-end biometrics services for high-complexity clinical programs.
What Sets MMS Apart in Client Service
MMS supports clients by leveraging its data-focused people, processes, and platforms in a way that enhances both speed and quality. Highlights of its approach include:
- Deep scientific and regulatory expertise that integrates seamlessly with Sponsor teams
- Exceptionally low annual global team turnover, allowing for long-term continuity and knowledge retention on every program
- Full end-to-end biometrics services embedding quality by design principles to de-risk development from trial design to submission
- Proactive communication and planning, especially in dual FDA/EMA submissions and accelerated pathways
- Custom data analytics via Datacise®, providing actionable real-time visibility into study progress, supporting sponsor oversight and enabling ICH E6 (R3) compliance
- A culture driven by SOUL (Sense of Urgency and Leadership), reflected in every interaction
“Being named a finalist for Excellence in Client Service means that even the micro-decisions that we make on a daily basis are being recognized and are having a material impact on our clients’ success in an increasingly complex regulatory and development environment,” said Ben Dudley, Chief Commercial Officer at MMS.
MMS continues to expand its offerings, recently integrating KerusCloud®, a cloud-based statistical modeling platform, and enhancing its end-to-end REMS services through proprietary technology and regulatory leadership. These advancements, coupled with the company’s commitment to excellence, demonstrate how MMS continues to lead in service, science, and strategic partnerships.
Winners will be announced in the Fierce CRO Report on Wednesday, June 18. To learn more about MMS and its global services, visit www.mmsholdings.com, and see the full list of finalists at https://www.fiercecroawards.com/fiercecroawardscom/finalists.
About MMS
MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating. For more information, visit www.mmsholdings.com.
Media Contact
Don F. McLean, dmclean1@mmsholdings.com
###